
Abritiga 250mg Tablet
Marketer
Zee Laboratories
Salt Composition
Abiraterone Acetate (250mg)
Overview Abritiga 250mg Tablet
Enzalutamide 250mg tablets are indicated for prostate cancer management. This medication may also treat other conditions as directed by your physician, sometimes as part of a broader chemotherapy regimen. Avoid taking Enzalutamide 250mg on an empty stomach; food consumption may exacerbate side effects. Dosage and frequency are determined by your doctor based on your individual needs and may vary over time. Strict adherence to your doctor's prescribed regimen is crucial, as incorrect usage or overdosage can lead to severe adverse reactions. Therapeutic benefits may not be immediately apparent and may take weeks or months to manifest; discontinue use only as per your physician's instructions. Common side effects include nausea, hypokalemia, edema, leukopenia, and fatigue. Report any concerning or persistent side effects to your doctor; mitigating strategies may be available. Less frequent but serious side effects, suggesting liver dysfunction, include jaundice, anorexia, dyspnea, dark urine, and nausea. Your doctor may monitor liver function, blood pressure, and potassium levels. Prior to commencing treatment, inform your doctor of any pre-existing hypertension, cardiac, hepatic, or renal conditions, or concurrent use of antimicrobial agents. Interaction with other medications is possible; provide a comprehensive list of all current medications to your physician. This medication is contraindicated during pregnancy and lactation due to potential harm to the fetus. Effective contraception for both partners is essential throughout treatment. Regular blood glucose monitoring may be required.
Uses of Abritiga 250mg Tablet
Malignancy of the prostate gland
Major Benefits of Abritiga 250mg Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Abritiga 250mg tablets should be administered on an empty stomach.
Common Side effects of Abritiga 250mg Tablet:
- Edema (swelling)
- Vomiting
- Decreased potassium level in blood
- Fatigue
- Anemia (low number of red blood cells)
- Urinary tract infection
- Diarrhea
- High blood pressure
- Cough
- Joint swelling
How to use Abritiga 250mg Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Abritiga 250mg tablets should be administered on an empty stomach.
How Abritiga 250mg Tablet works:
Abritiga 250mg tablets are used in cancer treatment. Their mechanism of action involves suppressing androgen synthesis in men. This is achieved through the inhibition of CYP17, a key enzyme in androgen production, thereby hindering prostate cancer progression.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Abritiga 250mg Tablet lacks established safety data. Seek medical advice before combining them.
PregnancyUNSAFE
Use of Abritiga 250mg tablets is strongly contraindicated during pregnancy. Pregnant women should consult their physician; research in animal and human studies reveals substantial risks to the fetus.
Breast feedingUNSAFE
The medication Abritiga 250mg Tablet is contraindicated for breastfeeding mothers. Evidence indicates a potential risk of infant toxicity.
DrivingSAFE
Driving ability is typically unaffected by Abritiga 250mg tablets.
KidneyCAUTION
Patients with severe kidney impairment should use Abritiga 250mg tablets cautiously; dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should use Abritiga 250mg tablets cautiously; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Abritiga 250mg Tablet :
Omit any missed Abritiga 250mg Tablet dose; resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Abritiga 250mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Androstenedione derivative |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
